

- A
- Age > 18 years
 - Patients treated for a PDAC

818 patients in the cohort

1st line:

683 patients received at least 1 chemotherapy line

7 patients excluded
(missing data)

676 patients kept for analysis

2nd line:

438 patients received a 2nd chemotherapy line

Cycle1, Day1

187 died or were lost from follow-up without benefiting from a 3rd line chemotherapy

251 proceeded to 3rd line chemotherapy

3rd line:

Death/ loss

from f.u. or 3rd line initiation


Analysis of proceeding to 3rd line according to the sequence type

B

Sequence	2 nd line (total=438) N (%)	3 rd line (total=251) N (%)	Proportion of patients in 2 nd line proceeding to 3 rd line
L1=FU based and L2=FU based	69 (16%)	47 (19%)	68%
L1=FU based and L2=Gem	118 (27%)	58 (23%)	49%
L1=FU based and L2=Gem combi	86 (20%)	48 (19%)	56%
L1=Gem combi and L2 =FU based	29 (7%)	21 (8%)	72%
L1=Gem and L2= FU based	33 (8%)	15 (6%)	45%
Sequence=Other	103(24%)	62 (25%)	60%

C

Probability to proceed to 3rd line



Probability to proceed to 3rd line

